Analyst Price Targets — CTEV
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 20, 2026 4:25 pm | Glen Santangelo | Barclays | $40.00 | $34.57 | TheFly | Claritev price target raised to $40 from $28 at Barclays |
| August 12, 2026 1:02 pm | Jessica Tassan | Piper Sandler | $73.00 | $35.36 | StreetInsider | Claritev (CTEV) PT Raised to $73 at Piper Sandler, 'Buyers of CTEV on Strong 2Q26' |
| August 10, 2026 11:13 am | — | Canaccord Genuity | $43.00 | $32.59 | TheFly | Claritev price target raised to $43 from $37 at Canaccord |
| July 21, 2026 10:51 am | — | Canaccord Genuity | $37.00 | $30.12 | TheFly | Claritev price target raised to $37 from $32 at Canaccord |
| June 3, 2026 5:26 pm | — | Piper Sandler | $61.00 | $25.00 | TheFly | Claritev price target lowered to $61 from $90 at Piper Sandler |
| April 24, 2026 8:34 am | — | Barclays | $28.00 | $20.30 | TheFly | Claritev initiated with an Overweight at Barclays |
| February 24, 2026 11:36 am | Stan Berenshteyn | Wells Fargo | $30.00 | $23.23 | TheFly | Claritev price target lowered to $30 from $33 at Wells Fargo |
| February 24, 2026 11:29 am | — | Guggenheim | $38.00 | $23.23 | TheFly | Claritev price target lowered to $38 from $43 at Guggenheim |
| January 8, 2026 9:21 pm | Stan Berenshteyn | Wells Fargo | $33.00 | $31.21 | TheFly | Claritev initiated with an Equal Weight at Wells Fargo |
Latest News for CTEV
MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that members of its management team will meet with investors at the following events in September 2026: Wells Fargo 21st Annual Healthcare Conference – Wednesday, September 9, 2026, at the Encore Boston Harbor – one-on-one meetings J.P. Morgan 4th Annual…
MCLEAN, Va.--(BUSINESS WIRE)---- $CTEV #ClaimsManagement--Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that Marpai, Inc. (OTCQX: MRAI) has expanded its relationship with Claritev to bring comprehensive pre- and post-payment integrity capabilities to the health plans and claims it administers. Marpai currently uses Claritev's PHCS® Network to provide access…
Claritev Corp (NYSE:CTEV) on Friday reported better-than-expected second-quarter financial results and raised its FY26 sales guidance above estimates.
Claritev NYSE: CTEV reported second-quarter revenue growth, record bookings and higher cash flow, prompting the healthcare technology company to raise its full-year revenue, adjusted EBITDA and free-cash-flow outlook.
Claritev Corporation (CTEV) Q2 2026 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CTEV.
U.S. House Trading
No House trades found for CTEV.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.